Gilead Sciences, Inc. said the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion on July 23, 2026, recommending Trodelvy in combination with Keytruda for certain adults with previously untreated advanced triple-negative breast cancer. The proposed indication covers unresectable locally advanced or metastatic disease in patients whose tumours express PD-L1 with a combined positive score of at least 10.
The recommendation is an important regulatory step, but it is not final European Union marketing authorisation. The proposed label must still be approved by the European Commission, after which Gilead would need to secure pricing, reimbursement and formulary access across individual European markets before the combination could achieve broad routine use.
Clinically, the decision advances a strategy that replaces the conventional chemotherapy component of first-line pembrolizumab treatment with a Trop-2-directed antibody-drug conjugate. Trodelvy, also known as sacituzumab govitecan, delivers the topoisomerase I inhibitor payload SN-38 to Trop-2-expressing cells, while Keytruda, or pembrolizumab, maintains immune checkpoint inhibition through PD-1 blockade.
The CHMP recommendation was supported by the randomised Phase 3 ASCENT-04/KEYNOTE-D19 trial, which produced a statistically significant improvement in progression-free survival against Keytruda combined with investigator-selected chemotherapy. The study has also been published in The New England Journal of Medicine, giving regulators and clinicians access to a substantially more mature evidence package than a preliminary company announcement or conference abstract alone.
Why is the CHMP opinion important when European Commission authorisation is still pending?
A positive CHMP opinion represents the scientific recommendation that normally precedes a European Commission decision under the European Union’s centralised authorisation procedure. The European Commission generally aims to adopt its decision within 67 days of an EMA opinion, although the precise timing can vary as the final product information and legally binding authorisation are completed.
The EMA has already published the proposed wording of the new indication. It specifies Trodelvy in combination with pembrolizumab for adults with unresectable locally advanced or metastatic triple-negative breast cancer who have received no prior systemic treatment for metastatic disease and whose tumours have a PD-L1 combined positive score of 10 or greater. The updated European summary of product characteristics will be published only after the European Commission grants the variation to Trodelvy’s existing marketing authorisation.
This distinction matters editorially and commercially. Gilead has crossed the principal scientific review hurdle, but the company cannot treat the recommendation as a completed European label expansion. Hospitals and oncologists will also need the final prescribing information, including dosing, safety management and patient-selection details, before implementation planning can move from expectation to execution.
Even after European Commission authorisation, patient access will not become uniform overnight. A centralised authorisation permits marketing across the European Union, but pricing and reimbursement decisions remain largely within national healthcare systems. Differences in health technology assessment, budget negotiations and launch sequencing can therefore create substantial gaps between regulatory approval and practical availability.
How persuasive is the ASCENT-04 evidence supporting Trodelvy instead of chemotherapy?
ASCENT-04/KEYNOTE-D19 enrolled 443 patients with previously untreated, PD-L1-positive advanced triple-negative breast cancer. Participants were randomly assigned in a one-to-one ratio to receive Trodelvy plus Keytruda or Keytruda with chemotherapy, which could include gemcitabine and carboplatin, paclitaxel or nab-paclitaxel. Although the trial was open label, the primary endpoint was progression-free survival assessed through blinded independent central review, reducing the risk that investigator knowledge of treatment assignment would determine the principal efficacy result.
Median progression-free survival reached 11.2 months with Trodelvy plus Keytruda, compared with 7.8 months for Keytruda plus chemotherapy. The hazard ratio was 0.65, corresponding to a 35% reduction in the risk of disease progression or death during the analysed period, with a two-sided P value below 0.001.
The approximately 3.4-month improvement in median progression-free survival is clinically relevant in an aggressive metastatic setting, particularly because many patients may progress rapidly and never reach later treatment lines. It also answers a commercially important question for Gilead: whether Trodelvy can create greater value when used before conventional chemotherapy resistance and cumulative treatment burden become established.
The trial does not demonstrate that Trodelvy plus Keytruda eliminates the need for cytotoxic treatment. Sacituzumab govitecan itself carries a cytotoxic payload and produces clinically significant haematological and gastrointestinal toxicity. The strategic change is therefore not a move from chemotherapy to a toxicity-free targeted regimen. It is a shift from traditional systemic chemotherapy to targeted delivery of a topoisomerase I inhibitor through an antibody-drug conjugate.
Why could response durability matter as much as the progression-free survival result?
The objective response rate was 60% with Trodelvy plus Keytruda and 53% with chemotherapy plus Keytruda. The difference is supportive but less striking than the progression-free survival result. A more distinctive finding was the reported median duration of response, which reached 16.5 months with the Trodelvy combination compared with 9.2 months in the control group.
That result suggests the combination’s advantage may relate not only to producing additional responses, but also to maintaining disease control for longer among patients who respond. Duration of response is especially relevant in metastatic triple-negative breast cancer because rapid progression can reduce performance status, narrow later-line options and increase the clinical consequences of an early treatment failure.
However, duration of response remains a secondary endpoint and should not be presented as proof of an overall survival advantage. Overall survival data were immature when the primary results were published. Longer follow-up will be needed to establish whether delayed progression and more durable responses translate into longer life, particularly in a study that allowed patients assigned to chemotherapy to receive Trodelvy after progression.
The crossover design is patient-centred because it provided access to Trodelvy after control-arm progression. Statistically, however, crossover can reduce the apparent separation in overall survival between treatment groups because some patients initially assigned to the comparator later receive the experimental medicine.
What safety trade-offs could influence first-line adoption of Trodelvy plus Keytruda?
Grade 3 or higher adverse events occurred in 71% of patients receiving Trodelvy plus Keytruda and 70% of patients receiving chemotherapy plus Keytruda. Adverse events leading to death occurred in approximately 3% of patients in each arm. These findings do not support describing the Trodelvy regimen as broadly safer, but they indicate that severe toxicity was not more frequent overall than with the control strategies used in the trial.
The toxicity patterns differed. Grade 3 or higher neutropenia occurred in 43% of patients receiving Trodelvy plus Keytruda, while grade 3 or higher diarrhoea occurred in 10%. In the chemotherapy control group, frequent severe events included neutropenia, anaemia and thrombocytopenia.
Treatment discontinuation due to adverse events occurred in 12% of patients assigned to Trodelvy plus Keytruda, compared with 31% of patients receiving chemotherapy plus Keytruda. The lower discontinuation rate could be clinically meaningful because maintaining an effective first-line regimen may help preserve disease control, although discontinuation can be affected by the toxicity profiles and dosing characteristics of individual chemotherapy choices.
Routine adoption would still require oncology centres to manage neutropenia, diarrhoea, nausea, infusion reactions and other known adverse effects associated with Trodelvy. The medicine is administered intravenously on days one and eight of a 21-day cycle, creating a continuing infusion and monitoring burden rather than an operationally simple treatment pathway.
The final European product information will be important because it will define the authorised risk-management instructions for the new combination. United States prescribing information may provide relevant clinical context, but it should not be substituted for the eventual European summary of product characteristics.
Could the varied chemotherapy control group complicate interpretation of the trial?
The study’s control arm allowed three chemotherapy approaches, reflecting real-world treatment variation but also creating analytical complexity. A subsequent New England Journal of Medicine correspondence argued that the progression-free survival difference appeared greater against gemcitabine and carboplatin than against taxane-based treatment, where the reported subgroup difference was not statistically significant.
That observation should not be treated as overturning the trial. ASCENT-04 was powered to compare the full Trodelvy plus Keytruda arm against the combined chemotherapy plus Keytruda control group, not to produce definitive conclusions within every chemotherapy subgroup. Smaller subgroup populations produce wider confidence intervals and greater uncertainty.
Nevertheless, the variation may matter in clinical decision-making. Oncologists could examine whether the expected advantage changes according to the chemotherapy regimen they would otherwise select, prior exposure in earlier-stage disease, disease tempo, organ involvement and individual tolerance for neutropenia, diarrhoea or taxane-associated toxicities.
The unresolved overall survival result will be another consideration. Progression-free survival is a recognised and relevant endpoint in metastatic cancer, but mature survival and quality-of-life findings would provide a more complete assessment of whether the regimen improves outcomes that matter most to patients.
How could the opinion establish Trodelvy across first-line metastatic TNBC segments?
The European Commission approved Trodelvy monotherapy in June 2026 for previously untreated advanced triple-negative breast cancer patients who are not candidates for PD-1 or PD-L1 inhibitor therapy. The new CHMP recommendation addresses the complementary group whose tumours express PD-L1 at a combined positive score of at least 10 and who can receive pembrolizumab.
If the combination indication receives European Commission authorisation, Gilead would have a Trodelvy-based first-line strategy spanning two clinically defined populations: monotherapy for patients who are not candidates for checkpoint inhibition and combination treatment for PD-L1-positive patients eligible for Keytruda.
That would be strategically more significant than a conventional incremental label expansion. Trodelvy was initially established in later-line metastatic disease, where treatment duration and eligible patient numbers can be constrained by previous progression and declining health. Movement into first-line treatment expands the potential duration of therapy and places the medicine closer to the beginning of the treatment pathway.
Gilead reported Trodelvy sales of $402 million during the first quarter of 2026, representing growth of 37% from the comparable period a year earlier. Full-year 2025 sales had reached approximately $1.4 billion. First-line regulatory expansion could support further growth, although the eventual contribution will depend on launch timing, reimbursement, competitive positioning and the speed at which oncologists alter established treatment practices.
Merck & Co., Inc. also stands to reinforce Keytruda’s role in the treatment pathway if the combination is authorised and adopted. The regimen retains pembrolizumab as the immunotherapy backbone while changing its cytotoxic partner, potentially extending Keytruda’s first-line relevance as antibody-drug conjugates move earlier in breast cancer treatment.
Why was Gilead’s stock reaction modest despite the regulatory de-risking?
Gilead Sciences shares ended July 23 at approximately $130.80, recording only a modest daily increase. The stock remained down roughly 4% over one week but was up approximately 4.6% over the preceding month, while trading between about $108 and $157 during the previous 52 weeks.
The muted immediate reaction suggests investors may have viewed the CHMP recommendation as an expected regulatory step rather than a major surprise. The ASCENT-04 results had already been presented and peer reviewed, and the United States Food and Drug Administration approved the same first-line Trodelvy strategy in June 2026. The stock movement also cannot be attributed solely to the European opinion because broader portfolio, earnings and market factors affect Gilead’s valuation.
Investor attention is likely to move towards the European Commission decision, national reimbursement progress, early prescribing trends and evidence that first-line uptake is expanding Trodelvy revenue without creating disproportionate commercial or manufacturing costs.
The CHMP decision confirms that European regulators consider the ASCENT-04 benefit-risk package sufficient to recommend the new indication. The decisive test now is whether final authorisation, national market access and clinician confidence convert a statistically strong progression-free survival result into sustained first-line use across European oncology practice.
